PULSE the living trend engine
▲ Peaking Health

Stronger than Ozempic. Not exactly legal. ‘Reta’ has entered the chat.

An unapproved, ultra‑potent weight‑loss drug dubbed ‘Reta’ is sparking hospitalisations and reports of yellow eyes across the U.S.

6sources
6articles
4velocity
+31%since first seen
2h agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

An experimental weight‑loss injection, described by The Washington Post as stronger than Ozempic and named ‘Reta’, is circulating without regulatory approval. Media reports note its sale at a Brooklyn bodega and label it an unlicensed ‘quick fix’ for weight loss. Coverage highlights a cluster of health concerns: users have developed yellowing of the eyes, liver damage and a wave of hospitalisations.

LADbible, The Sun and AFR report visual symptoms and liver injury, while CBS News and AOL.com focus on the illegal retail channel. The Washington Post frames the drug’s potency against approved therapies. Future reporting will likely track regulatory actions, additional hospital case counts and any expansion of the drug’s distribution.

Observers will watch for statements from health agencies and potential legal steps against sellers.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.

Quick answers

What is the drug being discussed?

The drug is an unapproved, experimental weight‑loss injection referred to as “Reta” and described as stronger than Ozempic.

What health effects have been reported?

Users have experienced yellowing of the eyes, liver damage and a wave of hospitalisations, according to multiple outlets.

Where has the drug been found for sale?

Coverage indicates it was sold at a Brooklyn bodega.

Coverage (6)

Topics

Reta weight‑loss drug Brooklyn hospitalisations Ozempic

Related trends